Cluster: Archive

More

Vasella reveals the chemistry behind Novartis

This content was published on Jul 13, 2003 But Vasella told swissinfo in an exclusive interview that it is uncertain that a merger will ever happen. Vasella explains that the 32.7 per cent Novartis stake in Roche is a long-term strategic investment. A merger, he feels, would have job creation potential for Basel and would strengthen competitiveness. Vasella, who has led Novartis since…